课题基金 / 基金详情

Study of TTP: Incidence Rates and Risk Factors

Study of TTP: Incidence Rates and Risk Factors
TTP 研究:发生率和危险因素
批准号:
6656361
负责人:
CHARLES L. BENNETT
金额:
$63.36万
依托单位国家:
美国
项目类别:
财政年份:
2002
资助国家:
美国
项目状态:
已结题
起止时间:
2002-09-09 至 2006-08-31

项目摘要

项目成果

CHARLES L. BENNETT的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Thrombotic thrombocytopenic purpura (TTP) is a life-threatening disease characterized by a pentad of symptoms including microangiopathic hemolytic anemia (MAHA), thrombocytopenia, neurologic symptoms, fever, and renal dysfunction. The diagnosis of TIP must be made in a timely manner because this condition carries with it a high mortality rate if untreated. Prompt therapy reduces substantially the mortality rate and therefore timely recognition is essential. TTP is a rare disease with an estimated annual incidence of 3.7 cases per million, and is more frequent among women. Recently, concerns have been raised that the annual incidence of TTP has increased 5 to 8 fold as a complication of therapy with commonly used antiplatelet drugs or following commonplace interventional procedures such as arterial stents. As with other rare diseases, there are significant gaps in the understanding of the pathogenesis of TTP, its distribution in the US population, risk factors, and determinants of outcome. We propose to evaluate gaps in our current knowledge of TTP among adults in the United States using a multi-center case-control study that addresses risk factors for TTP. In addition, we propose an interrelated set of translational basic science studies that may help improve our understanding of why some persons with TTP die from the illness. The primary objective of this study is to evaluate risk of incident TTP in relation to the use of antiplatelet drugs (the thienopyridines, ticlopidine and clopidogrel, the two most common non-transplant TTP-associated drugs identified in the FDA's passive surveillance program, MedWatch). Concern exists that there is a cause and effect relationship between clopidogrel, an agent that is used by two percent of the United States population, and TTP. A four year case control study is designed to investigate this specific question. The secondary objective of the study is to examine possible biologic markers as prognostic factors related to 30-day mortality following an incident TIP, including presence and activity of vWF cleaving metalloprotease, and degree of endothelial cell apoptosis. These issues are of particular relevance, as TTP is a serious and potentially fatal syndrome and has eluded scientific advances for the past seven decades. Our study is unique and will advance scientific knowledge in this area. The findings of this study would facilitate health care professional for future clinical actions and public policy decisions.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Southern Oncology Network on Adverse Reactions (SONAR) - Focus on Tyrosine Kinase
South Carolina Opioid Safety Initiative (SCOSI)
Research on Adverse Drug Events and Reports: Novel Multiple Myeloma Drugs
Research on Adverse Drug Events and Reports: Novel Multiple Myeloma Drugs
国内基金
海外基金
基于DNA甲基化交互网络的癌症hallmark挖掘及其在癌症转移biomarker筛选中的应用
  • 批准号:
    61602201
  • 项目类别:
    青年科学基金项目
  • 资助金额:
    20.0万元
  • 批准年份:
    2016
  • 负责人:
    周雄辉
  • 依托单位:
血清miRNAs成为一种新的biomarker在PD诊断中的价值和LRRK2基因调控的机制研究
  • 批准号:
    81170309
  • 项目类别:
    面上项目
  • 资助金额:
    50.0万元
  • 批准年份:
    2011
  • 负责人:
    颜桥
  • 依托单位:
非小细胞肺癌Biomarker的Imaging MS研究新方法
  • 批准号:
    30672394
  • 项目类别:
    面上项目
  • 资助金额:
    30.0万元
  • 批准年份:
    2006
  • 负责人:
    陆豪杰
  • 依托单位: